BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freeman LR, Aston-Jones G. Activation of medial hypothalamic orexin neurons during a Go/No-Go task. Brain Res 2020;1731:145928. [PMID: 30176242 DOI: 10.1016/j.brainres.2018.08.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. Medicine in Drug Discovery 2020;8:100059. [DOI: 10.1016/j.medidd.2020.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res 2020;1731:146665. [PMID: 31930996 DOI: 10.1016/j.brainres.2020.146665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Wiskerke J, James MH, Aston-Jones G. The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task. Brain Res 2020;1731:146222. [PMID: 31002819 DOI: 10.1016/j.brainres.2019.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 D'Souza MS. Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits. Front Psychiatry 2019;10:509. [PMID: 31396113 DOI: 10.3389/fpsyt.2019.00509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]